Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
- 1 October 1997
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 350 (9086), 1193-1198
- https://doi.org/10.1016/s0140-6736(97)09278-7
Abstract
No abstract availableKeywords
Funding Information
- Novartis
This publication has 30 references indexed in Scilit:
- Relevant targets for therapy with monoclonal antibodies in allograft transplantationKidney International, 1994
- THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG-TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2Transplantation, 1994
- EARLY VERSUS LATE ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1993
- THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTSTransplantation, 1992
- Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal AllograftsNew England Journal of Medicine, 1990
- INTERLEUKIN 2 RECEPTOR-TARGETED THERAPY—RATIONALE AND APPLICATIONS IN ORGAN TRANSPLANTATIONTransplantation, 1988
- PREVENTION OF REJECTION OF KIDNEY TRANSPLANTS BY MONOCLONAL ANTIBODY DIRECTED AGAINST INTERLEUKIN 2The Lancet, 1987
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985
- ANTITHYMOCYTE GLOBULIN AS THE PRIMARY TREATMENT FOR RENAL ALLOGRAFT REJECTIONTransplantation, 1983
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976